Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (10)
Type
Type
Guidance (285)
Guidance programme
(
1 selected
)
Guidance programme
Diagnostics guidance (1)
Health technology evaluations (6)
Highly specialised technologies guidance (1)
Interventional procedures guidance (6)
Medical technologies guidance (5)
Technology appraisal guidance (285)
Apply filters
Showing 211 to 220 of 285
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance and quality standards awaiting development
Title
Type
Rivaroxaban for treating chronic heart failure [ID1462]
Technology appraisal guidance
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]
Technology appraisal guidance
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764
Technology appraisal guidance
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763
Technology appraisal guidance
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]
Technology appraisal guidance
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]
Technology appraisal guidance
Sabizabulin for treating COVID 19 TS ID 11814
Technology appraisal guidance
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433
Technology appraisal guidance
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237
Technology appraisal guidance
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]
Technology appraisal guidance
Previous page
1
…
20
21
Current page
22
23
24
…
29
Page
22
of
29
Next page
Results per page
10
25
50
All
Back to top